Sirion, Bausch + Lomb sales and marketing update

Bausch + Lomb acquired U.S. rights to Zirgan 0.15% ganciclovir ophthalmic gel from Sirion. Last year, FDA approved Zirgan to treat acute herpetic keratitis; this April, Sirion launched the antiviral gel that targets viral DNA. Sirion has rights to the product under a 2007 deal with Laboratories Thea S.A. (Clermont Ferrand, France), which markets it outside the U.S. as Virgan. Financial terms were not disclosed. ...